標題: Titlebook: Cancer Immunology; Cancer Immunotherapy Nima Rezaei Book 20151st edition Springer-Verlag Berlin Heidelberg 2015 Cancer immunology.Cancer im [打印本頁] 作者: hierarchy 時間: 2025-3-21 18:42
書目名稱Cancer Immunology影響因子(影響力)
書目名稱Cancer Immunology影響因子(影響力)學(xué)科排名
書目名稱Cancer Immunology網(wǎng)絡(luò)公開度
書目名稱Cancer Immunology網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Cancer Immunology被引頻次
書目名稱Cancer Immunology被引頻次學(xué)科排名
書目名稱Cancer Immunology年度引用
書目名稱Cancer Immunology年度引用學(xué)科排名
書目名稱Cancer Immunology讀者反饋
書目名稱Cancer Immunology讀者反饋學(xué)科排名
作者: 結(jié)構(gòu) 時間: 2025-3-21 22:36
R. Achatzy,F. Daschner,N. Pittlik,F. Bartelsd encouraging results have been demonstrated both preclinically and in clinical trials. In this chapter we summarize the immunotherapeutic strategies for multiple myeloma together with the most up-to-date clinical trial outcomes.作者: 高腳酒杯 時間: 2025-3-22 01:27
B. Roth,G. Mattarelli,F. Bartelsoverview of candidate antigens to target in AML is given, followed by the currently described passive and active immunotherapeutic strategies. Active immunotherapy (e.g., modified leukemic cells, peptide, DNA, or dendritic cell-based vaccinations) requires a patient with an intact immune system and 作者: ITCH 時間: 2025-3-22 08:06 作者: 狂熱語言 時間: 2025-3-22 09:10 作者: 性別 時間: 2025-3-22 15:29
Joachim H.R. Lübke,Astrid Rollenhagennogenesis and progression has been unveiled. Cytokines and lymphokines such as interleukin-6 and lymphotoxin, together with immune cells such as tumor-associated macrophages, play an important role in this process. Disruption in normal immune regulatory mechanisms provides additional therapeutic tar作者: 性別 時間: 2025-3-22 20:18
Joachim H.R. Lübke,Astrid Rollenhagenhocytes (Treg). The present knowledge of the tumor microenvironment at the molecular and cellular levels is being used to reverse the situation in favor of the patient through targeted therapies such as the use of tyrosine kinase inhibitors or procedures that specifically activate an immune reaction作者: 希望 時間: 2025-3-23 00:04 作者: Individual 時間: 2025-3-23 04:27
Martin Middeke,Heinrich Holzgrevemor rejection rather than tolerance. This chapter will provide an overview of the immunomodulatory effects of nonsteroidal anti-inflammatory drugs (NSAIDs), statins, selective estrogen response modulators (SERMs), rexinoids, antidiabetic drugs, and natural agents (triterpenoids, phytochemicals, fatt作者: 鋼筆尖 時間: 2025-3-23 08:47
Joseph A. Ball,Israel Gohberg,Leiba Rodmannt treatment options and are held responsible for the initiation, metastasis, and recurrence of the disease. Thus, investigations on the interaction of CSCs with the host immune system have been performed, and targeting CSCs will potentially result in improved therapeutic outcome in the future.作者: Kindle 時間: 2025-3-23 12:36
Jean-Pierre Majoral,Anne-Marie Caminade with emphasis on humoral and cellular treatment modalities. Only recently, two monoclonal antibodies (mAbs), ipilimumab and nivolumab (BMS936558), have dramatically changed the outcome of melanoma treatments which were once almost nonexistent. In a dramatic analogy, these monoclonal antibodies seem作者: 外貌 時間: 2025-3-23 17:49
th the aim of educating clinicians on advances in cancer immunology and the most recent approaches in the immunotherapy of various tumors. This translational, clinically oriented book will be of special value to clinical immunologists, hematologists and oncologists.978-3-662-51384-2978-3-662-46410-6作者: 燒瓶 時間: 2025-3-23 19:06
Cancer Immunotherapy Confers a Global Benefit, addition, immunotherapy helps recover an injured or completely destroyed immune system after intensive cancer therapies as occurred in intensive chemotherapy schedules. A broad spectrum of immunotherapeutic medications has been developed to treat patients with cancers. Adoptive cell therapy, therap作者: 榨取 時間: 2025-3-23 22:18 作者: 粗語 時間: 2025-3-24 02:47
Immunopathology and Immunotherapy of Myeloid Leukemia,overview of candidate antigens to target in AML is given, followed by the currently described passive and active immunotherapeutic strategies. Active immunotherapy (e.g., modified leukemic cells, peptide, DNA, or dendritic cell-based vaccinations) requires a patient with an intact immune system and 作者: 故意 時間: 2025-3-24 07:59 作者: 罵人有污點 時間: 2025-3-24 11:12
Tumor Immunotherapy of Esophageal and Gastric Cancers,eveloped. This chapter reviews the promising strategies that employ monoclonal antibodies, adoptive cell transfer, and vaccine-based immunotherapy for the treatment of esophageal and gastric cancers. To date, several cancer vaccine trials have been performed in patients with advanced esophageal and 作者: maculated 時間: 2025-3-24 15:21
Immunopathology of Hepatobiliary Tumors and Immunotherapy of Liver Cancers,nogenesis and progression has been unveiled. Cytokines and lymphokines such as interleukin-6 and lymphotoxin, together with immune cells such as tumor-associated macrophages, play an important role in this process. Disruption in normal immune regulatory mechanisms provides additional therapeutic tar作者: chuckle 時間: 2025-3-24 21:28 作者: Oscillate 時間: 2025-3-25 01:13
Immunotherapy of Pancreatic Cancer,on, along with the development of early pancreatic tumors in mouse models have provided new opportunities for pancreatic cancer treatment and prevention. Immunotherapy for pancreatic cancer is a therapeutic approach that is designed to target pancreatic-cancer-associated antigens and regulatory sign作者: 發(fā)出眩目光芒 時間: 2025-3-25 04:39 作者: 包裹 時間: 2025-3-25 10:47
Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma,nt treatment options and are held responsible for the initiation, metastasis, and recurrence of the disease. Thus, investigations on the interaction of CSCs with the host immune system have been performed, and targeting CSCs will potentially result in improved therapeutic outcome in the future.作者: intuition 時間: 2025-3-25 14:18
Immunotherapy of Lung Tumors, with emphasis on humoral and cellular treatment modalities. Only recently, two monoclonal antibodies (mAbs), ipilimumab and nivolumab (BMS936558), have dramatically changed the outcome of melanoma treatments which were once almost nonexistent. In a dramatic analogy, these monoclonal antibodies seem作者: Arb853 時間: 2025-3-25 17:37 作者: 懶惰民族 時間: 2025-3-25 20:03
Fosfomycin in Cerebral and Spinal Abscesses,the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may作者: Flat-Feet 時間: 2025-3-26 03:03 作者: 繁忙 時間: 2025-3-26 05:29
R. Achatzy,F. Daschner,N. Pittlik,F. Bartels remain elusive. There has been an increased appreciation of the critical role host immunity plays in the evolution of disease and the potential therapeutic efficacy of immune-based therapies. These treatment approaches hold the potential promise of selective targeting of the malignant clone, disrup作者: Asperity 時間: 2025-3-26 11:52
B. Roth,G. Mattarelli,F. Bartelsoliferation, and resistance to apoptosis. It is now generally accepted that AML originates from genetic alterations in normal hematopoietic stem cells (HSC) or common myeloid progenitor cells, giving rise to the leukemic stem cell (LSC), from which the bulk of leukemic blasts arise, ultimately leadi作者: 拔出 時間: 2025-3-26 15:19
R. Achatzy,F. Daschner,N. Pittlik,F. Bartelsas targets for immunotherapy. Since CD20 is expressed in B-ALL cells, rituximab, an anti-CD20 antibody used in B-cell non-Hodgkin’s lymphomas (B-NHLs), has also been used in the ALL. Reports have shown that the addition of CD20 antibodies to conventional chemotherapy leads to a higher rate of comple作者: DAFT 時間: 2025-3-26 20:36
https://doi.org/10.1007/978-1-0716-4019-7other treatment modalities in the treatment of Hodgkin lymphoma (HL), attention has been drawn to immunotherapy as an efficient alternative or complement therapy. This chapter seeks to discuss a wide spectrum of immunotherapeutic approaches, from initial monoclonal antibodies to novel techniques dev作者: cortisol 時間: 2025-3-26 23:31 作者: AGGER 時間: 2025-3-27 04:02 作者: glomeruli 時間: 2025-3-27 06:08 作者: WAIL 時間: 2025-3-27 11:46
Joachim H.R. Lübke,Astrid Rollenhagennition, and (3) it is able to suppress immune reactivity. For colorectal cancer (CRC), there are many evidences connecting tumorigenesis and inflammation, such as the decreased incidence of tumors in individuals under nonsteroidal anti-inflammatory drug treatment. The increased incidence of tumors i作者: 上漲 時間: 2025-3-27 15:14
Cell Labeling and FIB–SEM Imagingtage of the cancer, and only a small population is potentially curative by surgical resection. Although gemcitabine-based chemotherapy is typically offered as standard of care, most patients do not survive longer than 6 months. FOLFIRINOX has shown superiority over gemcitabine monotherapy in metasta作者: Type-1-Diabetes 時間: 2025-3-27 19:20
Martin Middeke,Heinrich Holzgreve drugs are not well understood. Macrophages, regulatory T cells, dendritic cells, and pro-inflammatory cytokines modify the colon and pancreatic tumor microenvironments and contribute to tolerance to tumor-associated antigens and immune escape. The initiation and aggressive progression of disease in作者: Confidential 時間: 2025-3-28 00:10 作者: 使絕緣 時間: 2025-3-28 04:02
Joseph A. Ball,Israel Gohberg,Leiba Rodmance has been induced by cytotoxic T lymphocytes (CTLs), specific immune suppression is associated with tumor malignancy and progression. This contributes to unsatisfactory clinical outcome. In squamous cell carcinoma of the head and neck, the presence, activity, and also suppression of tumor-specific作者: certitude 時間: 2025-3-28 07:46 作者: rheumatology 時間: 2025-3-28 11:33
https://doi.org/10.1007/3-540-45731-3 of the first forms of immunotherapy for the treatment of sarcoma. With advancements in molecular oncology and the identification of specific sarcoma antigens, direct experimentation has been made possible in a variety of preclinical animal models. Discoveries from the laboratory have led to novel i作者: 火車車輪 時間: 2025-3-28 17:00
Piotr Guga,Andrzej Okruszek,Wojciech J. Stecdesigning effective immune-based therapeutic strategies. The immune response in the CNS has fundamental differences from that seen elsewhere in the organism. Moreover, a series of evasion mechanisms have been described for CNS tumors, which limit effective recognition and effective antitumoral cytot作者: 多嘴多舌 時間: 2025-3-28 19:33 作者: Spartan 時間: 2025-3-29 00:48 作者: 亞麻制品 時間: 2025-3-29 05:48
978-3-662-51384-2Springer-Verlag Berlin Heidelberg 2015作者: 填料 時間: 2025-3-29 08:28
Nima RezaeiUp-to-date review of cancer immunology.Bench to bedside approach to the immunology of cancers, with a focus on clinical aspects in order to educate clinicians in the clinical implications of recent re作者: FECT 時間: 2025-3-29 11:33
http://image.papertrans.cn/c/image/221126.jpg作者: Synapse 時間: 2025-3-29 19:38 作者: 藐視 時間: 2025-3-29 23:36
Vaccination in Human Solid Tumors: Recent Progress in the Clinical Arena,the immune response in vaccinated cancer patients was rarely associated with a significant clinical response. This chapter will discuss (a) the crucial issue of the most appropriate tumor antigens (self vs. mutated) to be used for vaccination in human solid tumors; (b) the different factors that may作者: dissent 時間: 2025-3-30 01:41 作者: 有害處 時間: 2025-3-30 07:03 作者: DOSE 時間: 2025-3-30 10:40 作者: START 時間: 2025-3-30 16:00 作者: 600 時間: 2025-3-30 19:03
Immunopathology and Immunotherapy of Hodgkin Lymphoma,other treatment modalities in the treatment of Hodgkin lymphoma (HL), attention has been drawn to immunotherapy as an efficient alternative or complement therapy. This chapter seeks to discuss a wide spectrum of immunotherapeutic approaches, from initial monoclonal antibodies to novel techniques dev作者: mortuary 時間: 2025-3-30 22:14
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, applying other treatment modalities in the treatment of non-Hodgkin’s lymphoma (NHL), as well as the considerable morbidity posed by the condition, attention has been drawn to immunotherapy as an efficient alternative or complement therapy. In light of the unique immunopathology of NHL, it is recog作者: 要控制 時間: 2025-3-31 04:38 作者: 時代錯誤 時間: 2025-3-31 05:14 作者: Obedient 時間: 2025-3-31 11:29 作者: 強有力 時間: 2025-3-31 14:07 作者: coltish 時間: 2025-3-31 19:22
Immune Modulation by Agents Used in the Prevention and Treatment of Colon and Pancreatic Cancers, drugs are not well understood. Macrophages, regulatory T cells, dendritic cells, and pro-inflammatory cytokines modify the colon and pancreatic tumor microenvironments and contribute to tolerance to tumor-associated antigens and immune escape. The initiation and aggressive progression of disease in作者: interior 時間: 2025-3-31 21:48 作者: NOVA 時間: 2025-4-1 04:31
Immunopathology of Head and Neck Tumors and Immunotherapy of Squamous Cell Carcinoma,ce has been induced by cytotoxic T lymphocytes (CTLs), specific immune suppression is associated with tumor malignancy and progression. This contributes to unsatisfactory clinical outcome. In squamous cell carcinoma of the head and neck, the presence, activity, and also suppression of tumor-specific作者: formula 時間: 2025-4-1 07:16
Immunotherapy and Immunosurveillance of Oral Cancers: Perspectives of Plasma Medicine and Mistletoetime, a second tumor, located at the kidney, however remained unaffected. The main difference in treatment being peritumoral vs. systematic application supports the hypothesis of immunosurveillance. The impact of mistletoe extract in direct contact with the tumor tissue might be explained by targete作者: FLIRT 時間: 2025-4-1 11:56
Immunopathology of Bone and Connective Tissue Cancers and Immunotherapy of Sarcomas, of the first forms of immunotherapy for the treatment of sarcoma. With advancements in molecular oncology and the identification of specific sarcoma antigens, direct experimentation has been made possible in a variety of preclinical animal models. Discoveries from the laboratory have led to novel i作者: Oligarchy 時間: 2025-4-1 16:18 作者: 使更活躍 時間: 2025-4-1 19:52
Immunotherapy of Lung Tumors,nly in some countries. The recent campaigns aimed at cessation of smoking have dramatically reduced cardiovascular events in some European countries. However, lung cancer remains an elusive disease with not much improvement in overall survival despite neoadjuvant chemotherapy, making this tumor a di作者: Dysarthria 時間: 2025-4-1 23:57 作者: Estrogen 時間: 2025-4-2 03:42 作者: 骯臟 時間: 2025-4-2 08:05
